Trial reportThe journal of headache and pain2020
Efficacy, tolerability, and safety of erenumab for the preventive treatment of persistent post-traumatic headache attributed to mild traumatic brain injury: an open-label study.
Trial report in The journal of headache and pain, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Open Label Study to Evaluate the Efficacy and Tolerability of Erenumab in the Prophylactic Treatment of Persistent Headache Attributed to Mild Traumatic Injury to the Head
Erenumab as a Therapeutic Approach for the Management of Trigeminal Neuropathic Pain (TNP)
Erenumab as a Therapeutic Approach for the Management of Painful Chronic Temporomandibular Disorders (TMD)
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.
- Evaluating the Phenotypic Patterns of Post-Traumatic Headache: A Systematic Review of Military Personnel.Military medicine · 2025Pooled it
- Serum calcitonin gene-related peptide in patients with persistent post-concussion symptoms, including headache: a cohort study.Journal of neurology · 2024Trial
- Hypersensitivity to PACAP-38 in post-traumatic headache: a randomized clinical trial.Brain : a journal of neurology · 2024Trial
- CGRP-induced migraine-like headache in persistent post-traumatic headache attributed to mild traumatic brain injury.The journal of headache and pain · 2022Trial
- Phenotype-guided Management of Post-traumatic Headache: An Update on Pathophysiology and Treatment.Current pain and headache reports · 2026Review
- CGRP-pathway exposure during the pre-EBP interval in spontaneous intracranial hypotension: an exploratory retrospective case series.BMC neurology · 2026Article
- Hallmarks of headache disorders: part 5 - secondary headaches.The journal of headache and pain · 2026Review
- CGRP and Migraine: Real-World Insights and Future Therapeutic Directions.Annual review of medicine · 2026Review
- Biofluid-based predictors of post-concussion symptoms: a narrative review of mild traumatic brain injury biomarkers.Brain communications · 2026Review
- Introduction of a classification interview for post-traumatic headache after concussion.The journal of headache and pain · 2025Article
- Pretreatment with an anti-CGRP monoclonal antibody attenuates mild TBI-induced tactile hypersensitivity in mice.The journal of headache and pain · 2025Article
- Calcitonin gene-related peptide monoclonal antibody treatment for new daily persistent headache.The journal of headache and pain · 2025Observational
- Raised intracranial pressure alters cortical vascular function and cephalic allodynia.Brain : a journal of neurology · 2025Article
- Targeting PACAP: Beyond Migraine to Cluster, Menstrual, and Post-traumatic Headaches.Advances in therapy · 2025Review
- Onabotulinumtoxin A for the Treatment of Post-Traumatic Headache: Is It Better than Anti-CGRP Antibodies?Toxins · 2024Review
- Can Long-Term Outcomes of Posttraumatic Headache be Predicted?Current pain and headache reports · 2024Review
- Pathology of pain and its implications for therapeutic interventions.Signal transduction and targeted therapy · 2024Review
- Treatment Options for Posttraumatic Headache: A Current Review of the Literature.Current pain and headache reports · 2024Review
- Inflammation, brain connectivity, and neuromodulation in post-traumatic headache.Brain, behavior, & immunity - health · 2024Review
- Traumatic brain injury: molecular biomarkers, genetics, secondary consequences, and medical management.Frontiers in neuroscience · 2024Review
Corrections and comments
- Commented on by
Authors and funding
15 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCalcitonin gene-related peptide (CGRP) has recently been implicated in the pathogenesis of post-traumatic headache (PTH), which raises the prospect for therapeutic use of monoclonal antibodies targeting CGRP or its receptor. Therefore, we decided to assess the efficacy, tolerability, and safety of erenumab for prevention of persistent PTH attributed to mild traumatic brain injury.
methodsA single-center, non-randomized, single-arm, open-label study of erenumab for adults aged 18-65 years with persistent PTH. Patients were assigned to receive 140-mg erenumab monthly by two subcutaneous 1-mL injections, given every 4 weeks for 12 weeks. The primary outcome measure was the mean change in number of monthly headache days of moderate to severe intensity from baseline (4-week pretreatment period) to week 9 through 12. Tolerability and safety endpoints were adverse events (i.e. number and type).
resultsEighty-nine of 100 patients completed the open-label trial. At baseline, the mean monthly number of headache days of moderate to severe intensity was 15.7. By week 9 through 12, the number was reduced by 2.8 days. The most common adverse events were constipation (n = 30) and injection-site reactions (n = 15). Of 100 patients who received at least one dose of erenumab, two patients discontinued the treatment regimen due to adverse events.
conclusionsAmong patients with persistent PTH, erenumab resulted in a lower frequency of moderate to severe headache days in this 12-week open-label trial. In addition, erenumab was well-tolerated as discontinuations due to adverse events were low. Placebo-controlled randomized clinical trials are needed to adequately evaluate the efficacy and safety of erenumab in patients with persistent PTH.
trial registrationClinicalTrials.Gov, NCT03974360. Registered on April 17, 2019 - Retrospectively registered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.